消化指南

订阅

MedSci主页 / 所有栏目 / 消化指南

2020 法国国家共识：炎症性肠病的管理指南

2020-11-04 国外消化科相关专家小组（统称） Dig Liver Dis . 2020 Nov 4;

炎症性肠病

在炎症性肠病（IBD）领域，新的治疗方法层出不穷。本文是对法国克罗恩病（CD）以及溃疡性结肠炎（UC）管理指南的更新。提供了最新的IBD患者管理指导。

中文标题：

2020 法国国家共识：炎症性肠病的管理指南

英文标题：

Clinical guidelines for the management of inflammatory bowel disease: Update of a French national consensus

发布机构：

国外消化科相关专家小组（统称）

发布日期：

2020-11-04

简要介绍：

在炎症性肠病（IBD）领域，新的治疗方法层出不穷。本文是对法国克罗恩病（CD）以及溃疡性结肠炎（UC）管理指南的更新。提供了最新的IBD患者管理指导。

 

相关资料下载：
[AttachmentFileName(sort=1, fileName=2020 法国国家共识：炎症性肠病的管理指南.pdf)] GetToolGuiderByIdResponse(projectId=1, id=315281c002013693, title=2020 法国国家共识：炎症性肠病的管理指南, enTitle=Clinical guidelines for the management of inflammatory bowel disease: Update of a French national consensus, guiderFrom=Dig Liver Dis . 2020 Nov 4;, authorId=0, author=, summary=在炎症性肠病（IBD）领域，新的治疗方法层出不穷。本文是对法国克罗恩病（CD）以及溃疡性结肠炎（UC）管理指南的更新。提供了最新的IBD患者管理指导。, cover=https://img.medsci.cn/20201127/1606490926008_2020535.jpg, journalId=0, articlesId=null, associationId=950, associationName=国外消化科相关专家小组（统称）, associationIntro=null, copyright=0, guiderPublishedTime=Wed Nov 04 00:00:00 CST 2020, originalUrl=, linkOutUrl=, content=<div class="one_info2" style="color: #373737;"> <div id="all_content"> <div class="editor_mirror editor_mirror_del"> <p>在炎症性肠病（IBD）领域，新的治疗方法层出不穷。本文是对法国克罗恩病（CD）以及溃疡性结肠炎（UC）管理指南的更新。提供了最新的IBD患者管理指导。</p> </div> </div> </div> <div class="box_info" style="color: #373737;">&nbsp;</div>, tagList=[TagDto(tagId=1125, tagName=炎症性肠病)], categoryList=[CategoryDto(categoryId=4, categoryName=消化, tenant=100), CategoryDto(categoryId=76, categoryName=胃肠外科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=1125, guiderKeyword=炎症性肠病, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=1, guiderRegion=4, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=7770, appHits=167, showAppHits=0, pcHits=1196, showPcHits=7603, likes=0, shares=9, comments=10, approvalStatus=1, publishedTime=Sat Nov 28 00:31:04 CST 2020, publishedTimeString=2020-11-04, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=qiushida2, createdTime=Fri Nov 27 23:28:55 CST 2020, updatedBy=2020535, updatedName=qiushida2, updatedTime=Sat Jan 06 20:17:57 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=2020 法国国家共识：炎症性肠病的管理指南.pdf)])
2020 法国国家共识：炎症性肠病的管理指南.pdf
下载请点击：
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1211652, encodeId=c511121165241, content=梅斯好强, beContent=null, objectType=guider, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1058119472, createdName=ms1000000366133195, createdTime=Sat Apr 16 14:06:06 CST 2022, time=2022-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=966183, encodeId=21a49661834d, content=不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210515/0e7300b0055443468a5bcded51092ef3/5e42cade18fb49659df04e11d94f77f1.jpg, createdBy=85331660234, createdName=云飞扬19910907, createdTime=Mon May 17 08:33:28 CST 2021, time=2021-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=960460, encodeId=01219604600a, content=不错，学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/RZGywIJic4Pw0RWreuzKrqbY22DMpQmibSB9ugvJWMOEhI9ib1628Km7RP8VjK8u4zuicj0azicEWmohsyoaNM2tgPQ/132, createdBy=9d4b5266389, createdName=小泽3960, createdTime=Sun Apr 25 20:01:55 CST 2021, time=2021-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=919693, encodeId=24d191969371, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=be0a5455466, createdName=ms8000001850328574, createdTime=Mon Jan 25 14:20:56 CST 2021, time=2021-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=913362, encodeId=e56d9133621f, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e9a61892495, createdName=ms4656773251161699, createdTime=Sun Jan 03 18:31:38 CST 2021, time=2021-01-03, status=1, ipAttribution=)]
    2022-04-16 ms1000000366133195

    梅斯好强

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1211652, encodeId=c511121165241, content=梅斯好强, beContent=null, objectType=guider, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1058119472, createdName=ms1000000366133195, createdTime=Sat Apr 16 14:06:06 CST 2022, time=2022-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=966183, encodeId=21a49661834d, content=不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210515/0e7300b0055443468a5bcded51092ef3/5e42cade18fb49659df04e11d94f77f1.jpg, createdBy=85331660234, createdName=云飞扬19910907, createdTime=Mon May 17 08:33:28 CST 2021, time=2021-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=960460, encodeId=01219604600a, content=不错，学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/RZGywIJic4Pw0RWreuzKrqbY22DMpQmibSB9ugvJWMOEhI9ib1628Km7RP8VjK8u4zuicj0azicEWmohsyoaNM2tgPQ/132, createdBy=9d4b5266389, createdName=小泽3960, createdTime=Sun Apr 25 20:01:55 CST 2021, time=2021-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=919693, encodeId=24d191969371, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=be0a5455466, createdName=ms8000001850328574, createdTime=Mon Jan 25 14:20:56 CST 2021, time=2021-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=913362, encodeId=e56d9133621f, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e9a61892495, createdName=ms4656773251161699, createdTime=Sun Jan 03 18:31:38 CST 2021, time=2021-01-03, status=1, ipAttribution=)]
    2021-05-17 云飞扬19910907

    不错

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1211652, encodeId=c511121165241, content=梅斯好强, beContent=null, objectType=guider, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1058119472, createdName=ms1000000366133195, createdTime=Sat Apr 16 14:06:06 CST 2022, time=2022-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=966183, encodeId=21a49661834d, content=不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210515/0e7300b0055443468a5bcded51092ef3/5e42cade18fb49659df04e11d94f77f1.jpg, createdBy=85331660234, createdName=云飞扬19910907, createdTime=Mon May 17 08:33:28 CST 2021, time=2021-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=960460, encodeId=01219604600a, content=不错，学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/RZGywIJic4Pw0RWreuzKrqbY22DMpQmibSB9ugvJWMOEhI9ib1628Km7RP8VjK8u4zuicj0azicEWmohsyoaNM2tgPQ/132, createdBy=9d4b5266389, createdName=小泽3960, createdTime=Sun Apr 25 20:01:55 CST 2021, time=2021-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=919693, encodeId=24d191969371, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=be0a5455466, createdName=ms8000001850328574, createdTime=Mon Jan 25 14:20:56 CST 2021, time=2021-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=913362, encodeId=e56d9133621f, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e9a61892495, createdName=ms4656773251161699, createdTime=Sun Jan 03 18:31:38 CST 2021, time=2021-01-03, status=1, ipAttribution=)]
    2021-04-25 小泽3960

    不错，学习了

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1211652, encodeId=c511121165241, content=梅斯好强, beContent=null, objectType=guider, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1058119472, createdName=ms1000000366133195, createdTime=Sat Apr 16 14:06:06 CST 2022, time=2022-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=966183, encodeId=21a49661834d, content=不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210515/0e7300b0055443468a5bcded51092ef3/5e42cade18fb49659df04e11d94f77f1.jpg, createdBy=85331660234, createdName=云飞扬19910907, createdTime=Mon May 17 08:33:28 CST 2021, time=2021-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=960460, encodeId=01219604600a, content=不错，学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/RZGywIJic4Pw0RWreuzKrqbY22DMpQmibSB9ugvJWMOEhI9ib1628Km7RP8VjK8u4zuicj0azicEWmohsyoaNM2tgPQ/132, createdBy=9d4b5266389, createdName=小泽3960, createdTime=Sun Apr 25 20:01:55 CST 2021, time=2021-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=919693, encodeId=24d191969371, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=be0a5455466, createdName=ms8000001850328574, createdTime=Mon Jan 25 14:20:56 CST 2021, time=2021-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=913362, encodeId=e56d9133621f, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e9a61892495, createdName=ms4656773251161699, createdTime=Sun Jan 03 18:31:38 CST 2021, time=2021-01-03, status=1, ipAttribution=)]
    2021-01-25 ms8000001850328574

    学习了

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1211652, encodeId=c511121165241, content=梅斯好强, beContent=null, objectType=guider, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1058119472, createdName=ms1000000366133195, createdTime=Sat Apr 16 14:06:06 CST 2022, time=2022-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=966183, encodeId=21a49661834d, content=不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210515/0e7300b0055443468a5bcded51092ef3/5e42cade18fb49659df04e11d94f77f1.jpg, createdBy=85331660234, createdName=云飞扬19910907, createdTime=Mon May 17 08:33:28 CST 2021, time=2021-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=960460, encodeId=01219604600a, content=不错，学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/RZGywIJic4Pw0RWreuzKrqbY22DMpQmibSB9ugvJWMOEhI9ib1628Km7RP8VjK8u4zuicj0azicEWmohsyoaNM2tgPQ/132, createdBy=9d4b5266389, createdName=小泽3960, createdTime=Sun Apr 25 20:01:55 CST 2021, time=2021-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=919693, encodeId=24d191969371, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=be0a5455466, createdName=ms8000001850328574, createdTime=Mon Jan 25 14:20:56 CST 2021, time=2021-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=913362, encodeId=e56d9133621f, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e9a61892495, createdName=ms4656773251161699, createdTime=Sun Jan 03 18:31:38 CST 2021, time=2021-01-03, status=1, ipAttribution=)]
    2021-01-03 ms4656773251161699

    学习了

    0

相关指南

炎症性肠病外科治疗专家共识

中华医学会消化病学分会炎症性肠病学组 · 2020-07-30

炎症性肠病病理诊断专家建议

中华医学会消化病学分会炎症性肠病学组 · 2020-03-30

2020 SICCR炎症性肠病立场声明：克罗恩病

意大利结直肠外科学会(SICCR,Italian society of colorectal surgery) · 2020-03-14

关于炎症性肠病患者有效预防和治疗SARS-CoV-2 感染的共识

中国医药教育协会 · 2020-02-20

2020 SICCR炎症性肠病立场声明：溃疡性结肠炎

意大利结直肠外科学会(SICCR,Italian society of colorectal surgery) · 2020-03-02

2020 KASID临床实践指南：炎症性肠病患者病毒性肝炎的预防和管理

国外消化科相关专家小组（统称） · 2020-01-28

拓展阅读

2014年加拿大炎症性肠病（IBD）与静脉血栓防治共识意见：加拿大胃肠病学会

加拿大胃肠病学协会(CAG,The Canadian Association of Gastroenterology) · 2014-03-01

2014 ESPGHAN儿童和青少年炎症性肠病诊断的波尔图标准（修订版）

欧洲儿科胃肠病学、肝病学和营养协会(ESPGHAN,European Society for Paediatric Gastroenterology, Hepatology, and Nutrition) · 2014-06-10

2014 CAG立场声明：应用巯嘌呤类药物治疗炎症性肠病

加拿大胃肠病学协会(CAG,The Canadian Association of Gastroenterology) · 2014-07-04

2015 ASGE指南：内镜检查在炎症性肠病中的作用

美国胃肠内镜学会(ASGE,American Society for Gastrointestinal Endoscopy) · 2015-03-20

2016 建立我国炎症性肠病诊治中心质量控制指标的共识

中华医学会消化病学分会炎症性肠病学组 · 2016-07-30

2017 IG-IBD临床实践指南：应用糖皮质激素和免疫抑制药物治疗炎症性肠病

意大利炎症性肠病研究组(IG-IBD,Italian Group for the Study of Inflammatory Bowel Disease) · 2017-01-25